1,720,995 research outputs found
miRNome analysis in psoriatic patients treated with anti IL- 23: a cohort study
Full text linkLo studio dei microRNA (miRNA) nella malattia psoriasica consente di esplorare sia gli aspetti irrisolti della patogenesi della malattia sia i meccanismi biologici alla base dell'efficacia o dell'inefficacia delle terapie più innovative attualmente disponibili. Inoltre, la terapia biologica con risankizumab, un anticorpo monoclonale anti-IL-23, è nota per la sua efficacia nel trattamento della psoriasi. Ad oggi, tuttavia, non ci sono studi che valutino la modulazione dei miRNA circolanti in relazione alla risposta individuale alla terapia anti-IL-23. Abbiamo quindi identificato, utilizzando tecnologie NGS e RT-PCR per la successiva validazione, i miRNA circolanti significativamente modulati prima e dopo il trattamento con risankizumab in pazienti con psoriasi. Inoltre, abbiamo valutato le variazioni della popolazione di Treg e di determinate citochine infiammatorie prima e dopo la terapia biologica con farmaco anti-IL-23. 12 pazienti affetti da psoriasi sono stati arruolati nello studio. Tutti i pazienti inclusi hanno mostrato una risposta ottimale alla terapia con risankizumab, con un miglioramento di tutti gli indici clinimetrici dopo un anno di terapia (PASI, BSA, PGA). Per quanto riguarda i cambiamenti più significativi nei microRNA circolanti, abbiamo identificato tre miRNA de-regolati, ossia miR-200a, miR-190a-5p e miR-148b-5p, dopo la terapia, i cui livelli sono risultati correlati agli indici di gravità della malattia rilevati al basale. L'analisi di validazione ha confermato una correlazione negativa tra il livello di espressione del miR-200a e l'indice PASI. E’ stato riscontrato inoltre un aumento dei Tregs circolanti dopo il trattamento in tutti i pazienti. Per quanto riguarda le citochine analizzate, abbiamo osservato una riduzione dei livelli di espressione di IL-23, IL-1beta e IL-8 nei PBMC dei pazienti psoriasici dopo la terapia con risankizumab. I nostri risultati rafforzano l'idea che specifici miRNA circolanti possano avere rilevanza clinica come biomarcatori diagnostici/prognostici della malattia psoriasica e suggeriscono la potenziale rilevanza di questi miRNA come biomarcatori della risposta al trattamento.The study of microRNAs (miRNAs) in psoriatic disease allows the exploration of both unresolved aspects of disease pathogenesis and the biological mechanisms underlying the efficacy or ineffectiveness of the most innovative therapies currently available. In addition, biological therapy with risankizumab, an anti-IL-23 monoclonal antibody, is known for its efficacy in the treatment of psoriasis. To date, however, there are no studies evaluating the modulation of circulating miRNAs in relation to the response individual to anti IL-23 therapy. We therefore identified, using NGS and RT-PCR technologies for subsequent validation, circulating miRNAs that were significantly modulated before and after risankizumab treatment in patients with psoriasis. In addition, we evaluated changes in the Treg population and selected inflammatory cytokines before and after
biological therapy with anti-IL-23 drug. Twelve patients with psoriasis were enrolled in the study. All included patients showed an optimal response to risankizumab therapy, with an improvement in all clinimetric indices after one year of therapy (PASI, BSA, PGA). Regarding the most significant changes in microRNAs circulating, we identified three de-regulated miRNAs, namely miR-200a, miR-190a-5p and miR-148b-5p, after therapy, whose levels were found to be correlated with the indices of disease severity detected at baseline. The analysis of validation confirmed a negative correlation between the level of expression of miR-200a and the PASI index. It was also found that there was an
increase in circulating Tregs after treatment in all patients. Regarding the cytokines analyzed, we observed a reduction in the IL-23, IL-1beta, and IL-8 expression levels in the PBMCs of patients with psoriatic patients after risankizumab therapy. Our results reinforce the idea that specific circulating miRNAs may have clinical relevance as diagnostic/prognostic biomarkers of psoriatic disease and suggest the potential relevance of these miRNAs as biomarkers of response to treatment
Novel Therapeutic Approaches and Targets for Treatment of Psoriasis
No full textPsoriasis is a multifactorial immune-mediated inflammatory disease, with a chronic relapsing-remitting course, which affects 2-3% of the worldwide population. Psoriasis involves skin, joints, or both, and it is associated with several comorbidities, including metabolic, rheumatological, cardiovascular, psychiatric complications, and other chronic inflammatory diseases, which are the expression of the complex underlying pathogenetic mechanism. An accurate characterization of the immune pathways involved in psoriasis led to recognize the new molecules, (IL)17 and 23, which become the new target of biologic therapy for moderate-to-severe plaque psoriasis
Saliva and Oral Diseases
No full textSaliva is a fascinating biological fluid which has all the features of a perfect diagnostic tool. In fact, its collection is rapid, simple, and noninvasive. Thanks to several transport mechanisms and its intimate contact with crevicular fluid, saliva contains hundreds of proteins deriving from plasma. Advances in analytical techniques have opened a new era-called "salivaomics"-that investigates the salivary proteome, transcriptome, microRNAs, metabolome, and microbiome. In recent years, researchers have tried to find salivary biomarkers for oral and systemic diseases with various protocols and technologies. The review aspires to provide an overall perspective of salivary biomarkers concerning oral diseases such as lichen planus, oral cancer, blistering diseases, and psoriasis. Saliva has proved to be a promising substrate for the early detection of oral diseases and the evaluation of therapeutic response. However, the wide variation in sampling, processing, and measuring of salivary elements still represents a limit for the application in clinical practice
Pyoderma gangrenosum succesfully treated with golimumab: Case report and review of the literature
No full textPyoderma gangrenosum (PG) is a rare neutrophilic dermatosis frequently related to chronic inflammatory bowel disease often associated with exacerbation of intestinal disease and/or loss of treatment efficacy. However, in patients with comorbidities, such as diabetes, the diagnosis may be a challenge. Here we report the case of DA, a 68-year-old man with a history of ulcerative recto-colitis (URC), type II diabetes and arterial hypertension, who had been treated with Infliximab and Adalimumab in the past. In September 2017, patient developed an erythematous, infiltrated and painful lesion of the third distal part of his left leg, with ulcerative evolution, rapidly worsened despite a broad.-spectrum antibiotc treatment had been introducted. A worsening of rectocolitis occurred simultaneously. In agreement with the gastroenterologists, patient started a new biological therapy with Golimumab, and oral prednisone with slow tapering of steroid dosage following the improvement of both cutaneous and intestinal symptoms. Dermatologists should be aware about the risk of PG in patient suffering from inflammatory bowel diseases, and consider this diagnosis in all patients affected by URC developing rapidly extending ulcerative skin lesion. Moreover therapeutic choice should take into consideration the effectiveness of golimumab on the inflammatory background which sustains both intestinal and skin disease in this type of patients. This article is protected by copyright. All rights reserved
Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience
No full textTelogen effluvium (TE) is one of the most common form of hair loss in women. Many triggers have been identified, as stress, drugs, trauma, endocrine disease, nutritional deficiencies, and febrile states. We report three cases of TE occurred after severe Sars-Cov-2 infection and provide our clinical management, according to Sars-Cov-2 hygiene measures. Only one case report has been found in the literature associating anagen effluvium during severe Sars-Cov-2 infection. Other studies reported the exacerbation of a preexisting TE, correlated to the stress of lockdown. In our cases, patients never had a TE diagnosis before and did not report previous evident hair loss. TE can be associated with post severe Sars-Cov-2 infection. From our revision of the literature, this is the first case-series describing TE in post severe Sars-Cov-2 patients. Further studies are needed to evaluate the relationship between TE and Sars-Cov-2 infection
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review
Full text linkBotulinum toxin is a superfamily of neurotoxins produced by the bacterium Clostridium Botulinum with well-established efficacy and safety profile in focal idiopathic hyperhidrosis. Recently, botulinum toxins have also been used in many other skin diseases, in off label regimen. The objective of this manuscript is to review and analyze the main therapeutic applications of botulinum toxins in skin diseases. A systematic review of the published data was conducted, following Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Botulinum toxins present several label and off-label indications of interest for dermatologists. The best-reported evidence concerns focal idiopathic hyperhidrosis, Raynaud phenomenon, suppurative hidradenitis, Hailey-Hailey disease, epidermolysis bullosa simplex Weber-Cockayne type, Darier's disease, pachyonychia congenita, aquagenic keratoderma, alopecia, psoriasis, notalgia paresthetica, facial erythema and flushing, and oily skin. Further clinical trials are still needed to better understand the real efficacy and safety of these applications and to standardize injection and doses protocols for off label applications
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
- …
